Niaspan®: Creating a new concept for raising HDL-cholesterol

European Heart Journal, Supplement

Volumn 7, Issue F, 2005, Pages

  McGovern, Mark ^a,b  

^a Kos Pharmaceuticals   (United States)

^b NONE   (United States)

Author keywords

Cardiovascular risk; Cholesterol; Dyslipidaemia; HMG CoA reductase inhibitors; Lipid profiles; Niaspan ; Nicotinic acid

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TRIACYLGLYCEROL;

ATHEROGENESIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; FLUSHING; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIVER TOXICITY; METABOLIC SYNDROME X; MUSCLE DISEASE; PRIORITY JOURNAL;

EID: 24944556347     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui042     Document Type: Conference Paper

References (32)

1. Abourjaily HM. A review of Niaspan, an extended-release niacin. Nutr Clin Care 2001;4:250-255.
2. Goldberg A, Alagona P Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-1105.
3. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
4. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47:1097-1104.
5. Kos Pharmaceuticals Inc. Pooled Analysis of Pivotal Studies, data on file.
6. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Institutes of Health/National Heart Lung and Blood Institute. www.nhlbi.nih.gov/guidelines/cholesterol.
7. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
8. Wolfe ML, Vartanian SF, Ross JL et al. Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476-479.
9. Insull W Jr, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-1127.
10. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-118.
11. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-672.
12. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U.
13. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998;82:82U-84U.
14. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4:228-236.
15. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-749.
16. Morgan JM, Capuzzi DM, Baksh RI et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-1436.
17. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6:179-188.
18. Grundy SM, Vega GL, McGovern ME et al.; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162: 1568-1576.
19. Grundy SM, Vega GL, McGovern ME et al. Comparative effects on lipids and glycemic control of niacin extended-release/lovastatin or fenofibrate in patients with diabetic dyslipidemia. (Abstract 29-LB). Presented at the 64th Scientific Sessions of the American Diabetes Association. 4-8 June 2004, Orlando, FL, USA.
20. Van JT, Pan J, Wasty T et al. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 2002;89:1306-1308.
21. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
22. McGovern ME, Malott CM, Simmons PD et al. Once-daily niacin-extended- release/lovastatin combination is effective and safe for treatment of dyslipidaemia associated with metabolic syndrome. (Abstract 820-5). Scientific session of the American College of Cardiology, 2004.
23. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805-807.
24. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992;93:102-104.
25. McKenney JM, Proctor JD, Harris S et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677.
26. Chang JT, Staffa JA, Parks M et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-426.
27. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004;147:956-965.
28. Jones PH, Davidson MH, Stein EA et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-160.
29. Ballantyne CM, Blazing MA, Hunninghake DB et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J 2003;46:862-869.
30. Al-Shaer MH, Choueiri NE, Suleiman ES. The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis 2004;3:22.
31. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003;10:63-71.
32. Bostom AG, Gagnon DR, Cupples LA et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994;90:1688-1695.